BioHarvest Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 8% year-over-year to $8.5M, with gross margin up to 59% and net loss at $2.6M. D2C and CDMO segments advanced, including a $1.2M fragrance contract and strong VINIA product adoption. Guidance for 2026 remains unchanged, with growth expected in H2.
Fiscal Year 2025
-
Q4 and full-year revenues grew 25% and 37% year-over-year, with gross margins improving to 58–59%. The D2C business, led by VINIA, achieved US category leadership, while the CDMO division advanced four major programs and expects to double or triple revenue in 2026.
-
Q3 2025 revenue grew 39% year-over-year to $9.1M, driven by core products and surging CDMO services. Gross margin improved to 61%, and recent $30.8M in financing fully funds expansion, including new product launches and manufacturing scale-up.
-
A major breakthrough in scalable plant exosome production positions the company for significant growth in cosmetics, nutraceuticals, and pharma, with patent protections in place. Commercialization is expected within 18-24 months, while new hydration products and an expanding Health Pros Affiliate system support the goal of Q4 adjusted EBITDA profitability.
-
A leading plant cell biology innovator detailed its dual business model, highlighting strong growth in direct-to-consumer health products and rapid expansion of its high-margin CDMO partnerships. The company projects further margin gains and positive EBITDA by year-end.
-
Q2 2025 revenue rose 41% to $8.5M with gross margin expanding to 60%. New product launches, Health Pros channel, and CDMO pipeline growth position the company for adjusted EBITDA breakeven in Q4 2025 and further margin gains, despite tariff headwinds.
-
Revenue rose 47% year-over-year to $7.9M, with gross margin up to 58.5% and net loss narrowing to $2.3M. The company advanced a major pharma CDMO contract, expanded its VINIA product line, and expects adjusted EBITDA break-even in H2 2025.
Fiscal Year 2024
-
Achieved 99% revenue growth in 2024, driven by Vinia and new product launches, with Q4 revenue up 62% year-over-year and gross margin reaching 57%. CDMO contracts and manufacturing scale-up support continued high growth, with adjusted EBITDA profitability targeted for the second half of 2025.
-
Q3 2024 revenue doubled year-over-year to $6.5M, driven by strong VINIA sales and subscriber growth, with gross margin up to 57%. CDMO services gained traction with two signed customers and a robust pipeline, while new product launches and margin optimization set the stage for continued growth and profitability in 2025.